Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine

Mette Stæhr, Kristian Bergholt Buhl, René F Andersen, Per Svenningsen, Flemming Nielsen, Gitte Rye Hinrichs, Claus Bistrup, Boye L Jensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

In nephrotic syndrome, aberrant glomerular filtration of plasminogen and conversion to active plasmin in preurine are thought to activate proteolytically epithelial sodium channel (ENaC) and contribute to sodium retention and edema. The ENaC blocker amiloride is an off-target inhibitor of urokinasetype plasminogen activator (uPA) in vitro. It was hypothesized that uPA is abnormally filtered to preurine and is inhibited in urine by amiloride in nephrotic syndrome. This was tested by determination of Na + balance, uPA protein and activity, and amiloride concentration in urine from rats with puromycin aminonucleoside (PAN)- induced nephrotic syndrome. Urine samples from 6 adult and 18 pediatric patients with nephrotic syndrome were analyzed for uPA activity and protein. PAN treatment induced significant proteinuria in rats which coincided with increased urine uPA protein and activity, increased urine protease activity, and total plasminogen/ plasmin concentration and Na + retention. Amiloride (2 mg·kg -1·24 h -1) concentration in urine was in the range 10 –20 µmol/l and reduced significantly urine uPA activity, plasminogen activation, protease activity, and sodium retention in PAN rats, while proteinuria was not altered. In paired urine samples, uPA protein was significantly elevated in urine from children with active nephrotic syndrome compared with remission phase. In six adult nephrotic patients, urine uPA protein and activity correlated positively with 24 h urine protein excretion. In conclusion, nephrotic syndrome is associated with aberrant filtration of uPA across the injured glomerular barrier. Amiloride inhibits urine uPA activity which attenuates plasminogen activation and urine protease activity in vivo. Urine uPA is a relevant target for amiloride in vivo.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Physiology: Renal Physiology
Vol/bind309
Udgave nummer3
Sider (fra-til)F235-F241
ISSN1931-857X
DOI
StatusUdgivet - 1. aug. 2015

Fingeraftryk

Dyk ned i forskningsemnerne om 'Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine'. Sammen danner de et unikt fingeraftryk.

Citationsformater